Abstract
Background: Given the role of EGFRm in the development of NSCLC, EGFR is an established target for treating the disease. While EGFR-TKIs are the recommended first-line (1L) treatment option for advanced EGFRm NSCLC, there is limited evidence describing the use of EGFR-TKIs in clinical practice. This study investigated the real-world treatment patterns in advanced EGFRm NSCLC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
